Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period

NCT04867616 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04867616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04867616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Completed
Start date
June 9, 2021
Completion date
August 1, 2025
Enrollment
466 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease